phone iconPhone: (401) 822-4673
phone iconFax: (401) 822-4676
Receive our Health e-Newsletter

News for Healthier Living

RAS(ON) Inhibitor Daraxonrasib Shows Promising Results in Advanced Pancreatic Cancer Phase 1/2 Study

The targeted RAS inhibitor daraxonrasib was found to be safe and showed signs of efficacy in a phase 1/2 first-in-human trial in patients with previously treated, RAS-mutant, metastatic pancreatic cancer, according to a clinical trial led at Dana-Farber Cancer Institute and across the country.

May 7, 2026


May 15 2026

May 14 2026

May 13 2026

May 12 2026

May 11 2026

May 10 2026

May 8 2026

May 7 2026

May 6 2026

May 5 2026

May 4 2026

May 1 2026

Angell Street Psychiatry
Copyright 2026 HealthBanks, Inc. All rights reserved.
Terms of Use | Privacy Policy